Phase II Trial of Motexafin Gadolinium With Whole Brain Radiation Therapy Followed by Stereotactic Radiosurgery Boost in the Treatment of Patients With Brain Metastases
Patients will receive three weeks of whole brain radiation therapy concurrent with daily
motexafin gadolinium during weeks 2 and 3, followed by a stereotactic radiosurgery boost
concurrent with motexafin gadolinium. Patients will be followed for radiologic response,
neurologic progression, and neurocognitive progression.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Rate of irreversible Grade 3 or any Grade 4 or 5 neurologic radiation toxicities occurring within 3 months following SRS boost.
Minesh P Mehta, MD
University of Wisconsin, Madison
United States: Food and Drug Administration
|Phoenix, Arizona 85012|
|Cleveland, Ohio 44195|
|Philadelphia, Pennsylvania 19104|
|Austin, Texas 78705|